B. Lum

1.4k total citations · 1 hit paper
9 papers, 1.1k citations indexed

About

B. Lum is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, B. Lum has authored 9 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in B. Lum's work include Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Research Studies (3 papers) and Cell death mechanisms and regulation (2 papers). B. Lum is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Research Studies (3 papers) and Cell death mechanisms and regulation (2 papers). B. Lum collaborates with scholars based in United States, Sweden and Canada. B. Lum's co-authors include Mitesh J. Borad, Charles M. Rudin, Walter C. Darbonne, Josina C. Reddy, James C. Marsters, Jennifer A. Low, Christine L. Hann, Raoul Tibes, Robert L. Yauch and Glen J. Weiss and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Pharmaceutical Research.

In The Last Decade

B. Lum

9 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

2009 833 citations Daniel D. Von Hoff, Patricia LoRusso et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by B. Lum

Since Specialization

Citations

This map shows the geographic impact of B. Lum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Lum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Lum more than expected).

Fields of papers citing papers by B. Lum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Lum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Lum. The network helps show where B. Lum may publish in the future.

Co-authorship network of co-authors of B. Lum

This figure shows the co-authorship network connecting the top 25 collaborators of B. Lum. A scholar is included among the top collaborators of B. Lum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Lum. B. Lum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory 2018 ·Pharmaceutical Research ·(unknown), Lena E. Friberg, B. Lum, Bei Wang, Angelica Quartino, Chunze Li, Sandhya Girish, Jin Y. Jin, Mats O. Karlsson	15
2	A phase I, open-label mass balance study of the hedgehog pathway inhibitor (HPI) GDC-0449 in healthy female subjects of non-childbearing potential. 2010 ·Journal of Clinical Oncology ·B. Lum, (unknown), Ilsung Chang, Karin Jorga, Cornelis E. C. A. Hop, Young G. Shin, Vikram Malhi, (unknown), Jennifer A. Low, Richard Graham	1
3	Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma breakdown → 2009 ·New England Journal of Medicine ·Daniel D. Von Hoff, Patricia LoRusso, Charles M. Rudin, Josina C. Reddy, Robert L. Yauch, Raoul Tibes, Glen J. Weiss, Mitesh J. Borad, Christine L. Hann, Julie R. Brahmer, Howard Mackey, B. Lum, Walter C. Darbonne, James C. Marsters, Frédéric J. de Sauvage, Jennifer A. Low	833
4	Population pharmacokinetic (PPK) analysis of recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) in a Phase 1a Study in advanced cancer and lymphoma 2008 ·Journal of Clinical Oncology ·Xin Yan, Tanyifor M. Tohnya, Ronald Herbst, David S. Mendelson, S. Gail Eckhardt, P J O'Dwyer, William Novotny, David E. Allison, B. Lum, Nelson L. ‘Shasha’ Jumbe	5
5	Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non–small cell lung cancer 2006 ·Clinical Pharmacology & Therapeutics ·Jianfeng Lü, Steve Eppler, (unknown), Marta Hamilton, Ashok Rakhit, René Bruno, B. Lum	190
6	Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma 2006 ·Journal of Clinical Oncology ·(unknown), Roy S. Herbst, David S. Mendelson, Sabine Eckhardt, Peter J. O’Dwyer, (unknown), Richard H. Osborne, Melissa Cheu, G. Lieberman, B. Lum	27
7	The effect of erlotinib on CYP3A4 activity, as quantified by the erythromycin breath test and oral midazolam kinetics in cancer patients: Preliminary results 2005 ·Journal of Clinical Oncology ·Hilary Calvert, Chris Twelves, Malcolm Ranson, Alan Anthoney, Ruth Plummer, (unknown), (unknown), B. Lum, Marta Hamilton, Ashok Rakhit	5
8	Tarceva™ (erlotinib) exposure/effects (EE) analysis from a Phase III study in advanced NSCLC: Effect of smoking on the PK of erlotinib 2005 ·Marta Hamilton, Julie Wolf, (unknown), Jianfeng Lü, B. Lum, Keyue Ding, Gary M. Clark, Ashok Rakhit, Lesley Seymour, (unknown), Jason Rusk, Frances A. Shepherd	16
9	Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC) 2004 ·Journal of Clinical Oncology ·Hai T. Tran, Ralph Zinner, George R. Blumenschein, Yun Oh, Vassiliki A. Papadimitrakopoulou, E. S. Kim, Charles Lu, (unknown), B. Lum, Roy S. Herbst	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact